Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Aug 23, 2024
Emerging Company Profile
Borealis: Versant, Novartis launch Chinook’s RNA-targeting sequel
The research team behind Chinook are taking on renal diseases with cell type-specific delivery of oligonucleotide therapies.
BioCentury | May 30, 2024
Product Development
Renal therapies get disease-specific
Endpoint innovation and success stories are driving a surge in renal disease drug development
BioCentury | Jan 6, 2024
Finance
Jan. 5 Quick Takes: Metagenomi, ArriVent file for IPO
Plus: Immunic eyes $240M private placement and updates from Applied Therapeutics and Novartis
BioCentury | Nov 17, 2023
Product Development
AstraZeneca looks to new CKD combinations to extend Farxiga’s reign
AZ is moving Farxiga combinations into Phase III testing that it believes can help reach underserved patient subsets
BioCentury | Oct 31, 2023
Finance
Oct. 30 Quick Takes: VCs pile in for MapLight’s $225M series C
Plus: Deciphera gets lift from TGCT readout and updates from Hengrui, Merck KGaA, AnHeart, Nippon Kayaku, Novartis, GSK and more
BioCentury | Jun 12, 2023
Deals
Seeking high-value drugs, Novartis adds kidney franchise in $3.2B Chinook takeout
Biotech’s later-stage candidates give pharma two chances at a blockbuster, starting with IgA nephropathy indication amid rising competition
BioCentury | Mar 8, 2023
Distillery Therapeutics
Inhibiting endothelin A receptor for acute kidney injury sequelae
BioCentury | Feb 18, 2023
Regulation
FDA’s Filspari approval opens Travere’s two-year window
Travere aims to establish Filspari as standard of care in IgA nephropathy, even with the drug’s liver toxicity monitoring and restricted label
BioCentury | Aug 31, 2021
Regulation
Turning biomarkers into surrogates, starting with the familiar
Mining decades of clinical practice, three fields are making surrogate endpoints out of common prognostic markers
BioCentury | Aug 16, 2021
Product Development
Travere readout in IgA nephropathy sets up accelerated path to rival Calliditas’ therapy
Positive interim data for sparsentan, a dual angiotensin and endothelin receptor antagonist
Items per page:
1 - 10 of 389